OptiNose

OptiNose — Q3 2022 Earnings Presentation

20 slides from OptiNose's earnings presentation, Nov 10, 2022

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n N o v e m b e r 1 0 , 2 0 2 2 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this

  3. Slide 3: Q3 2022 Performance

    optinose_ ——— Q3 2022 Performance

  4. Slide 4: Key Takeaways

    4 Key Takeaways Met with FDA in Q3 2022 to Discuss CS Data Submission CS is a 10-fold Market Opportunity for XHANCE Focused on Improving Profitability in 2023 While Preparing to Capitalize on a CS launch Expect to Submit sNDA in Early 2023 1 Millionth XHANCE Prescription Filled in Q3 2022

  5. Slide 5: ReOpen Program Update

    optinose_ ——— ReOpen Program Update

  6. Slide 6: CS Supplemental NDA - Anticipated Next Steps

    6 CS Supplemental NDA - Anticipated Next Steps  As planned, we met with FDA in September to discuss submission of our upcoming supplemental new drug application (sNDA) in pursuit of a new indication - We believe it was a positive meeting  Submission of the sNDA now expected in early 2023 - Previou

  7. Slide 7: ReOpen Program at Conferences

    7 ReOpen Program at Conferences  American Rhinologic Society (ARS) ‒ Re-Open-1: A randomized double-blind placebo-controlled trial of EDS-FLU for CRSwNP or CRSsNP ‒ Abstract presented at 68th Annual Meeting on September 9th  IDWeek 2022 ‒ Pooled Data: Exhalation Delivery System with Fluticasone (E

  8. Slide 8: Q3 2022 Commercial Update

    optinose_ —— Q3 2022 Commercial Update

  9. Slide 9: Successful Development of XHANCE as the First FDA-approved Drug Treatment for Chronic Sinusitis

    9 Successful Development of XHANCE as the First FDA-approved Drug Treatment for Chronic Sinusitis Creates Multiple New Opportunities for Growth Up to ~1 Million patients with nasal polyps (NP) are treated by specialty physicians in our current sales deployment $1B TAM $3B TAM Up to ~10 Million patie

  10. Slide 10: XHANCE New Prescriptions

    10 XHANCE New Prescriptions XHANCE New Prescriptions matched prior year in Q3 2022 and increased 3% on a Year-to-Date Basis Estimated based on monthly prescription data from third parties and XHANCE preferred pharmacy network. The Market on this slide is defined as the sum of all intranasal steroid

  11. Slide 11: XHANCE Total Prescriptions

    11 XHANCE Total Prescriptions Revised Co-Pay Assistance Program is Suppressing TRx of Unprofitable High-Deductible Type in 2022XHANCE Total Prescriptions matched prior year in Q3 2022 and increased 3% on a Year-to-Date Basis Estimated based on monthly prescription data from third parties and XHANCE

  12. Slide 12: XHANCE Market Share & Prescribers by Prescribing Frequency

    12 XHANCE Market Share & Prescribers by Prescribing Frequency The Market on this slide is defined as the sum of all intranasal steroid prescriptions written by physicians in the XHANCE target physician audience of approximately 21,000 physicians. Estimated based on monthly prescription data from thi

  13. Slide 13: Q3 2022 Financial Update

    optinose_ —— Q3 2022 Financial Update

  14. Slide 14: Financial Review – XHANCE Net Revenue

    14 Financial Review – XHANCE Net Revenue One-time refund of disputed rebates of ~$1.6M in Q3 2021 is the primary driver of Y/Y decrease in Q3 2022 XHANCE Net Revenue decreased 8% from Q3 2021 to Q3 2022 and increased 8% on a Year-to-Date Basis $21.8 $20.1 Q3 '21 Q3 '22 ($M) -8% Net Revenue Net Reven

  15. Slide 15: Financial Review – XHANCE Average Net Revenue per Prescription

    15 $253 $232 Q3 '21 Q3 '22 Financial Review – XHANCE Average Net Revenue per Prescription One-time refund of disputed rebates of ~$1.6M in Q3 2021 is the primary driver of Y/Y decrease in Q3 2022 XHANCE Average Net Revenue per TRx decreased from $253 to $232 from Q3 2021 to Q3 2022 and increased fro

  16. Slide 16: Financial Guidance

    16 Financial Guidance  XHANCE Net Revenue ‒ Expected to be between $74 - $78 million ‒ Previously expected to be between $85 - $92 million  XHANCE Average Net Revenue per Prescription ‒ FY 2022 expected to be approximately $220 ‒ Previously expected to exceed $220  Operating Expense (GAAP) ‒ Expe

  17. Slide 17: Closing Remarks

    optinose_ ——— Closing Remarks

  18. Slide 18: Key Takeaways

    18 Key Takeaways Met with FDA in Q3 2022 to Discuss CS Data Submission CS is a 10-fold Market Opportunity for XHANCE Focused on Improving Profitability in 2023 While Preparing to Capitalize on a CS launch Expect to Submit sNDA in Early 2023 1 Millionth XHANCE Prescription Filled in Q3 2022

  19. Slide 19: Investor Relations – Optinose

    19 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267-521-0531 [email protected] As of September 30, 2022: – $61.1 million in cash – Debt: $130 million – 83.5 million common shares o/s – 14.0 million options, warrants

  20. Slide 20: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n N o v e m b e r 1 0 , 2 0 2 2

OptiNose — Q3 2022 Earnings Presentation on 6ix